RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA
Delisted
RETA was delisted on the 25th of September, 2023.
186 hedge funds and large institutions have $2.13B invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2020 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 69 increasing their positions, 66 reducing their positions, and 47 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less funds holding
Funds holding: →
less funds holding in top 10
Funds holding in top 10: →
41% less capital invested
Capital invested by funds: $3.62B → $2.13B (-$1.49B)
43% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 47
Holders
186
Holding in Top 10
7
Calls
$36.9M
Puts
$29.6M
Top Buyers
| 1 | +$49.6M | |
| 2 | +$24.2M | |
| 3 | +$18.1M | |
| 4 |
CA
Corriente Advisors
Fort Worth,
Texas
|
+$14.9M |
| 5 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$13.2M |
Top Sellers
| 1 | -$55.5M | |
| 2 | -$36.5M | |
| 3 | -$31.2M | |
| 4 |
Westfield Capital Management
Boston,
Massachusetts
|
-$24.8M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$22.9M |